Notable insider buying and selling activity across public companies.
Tracking and analysis of reported insider transactions, including executive and director buying or selling. Insider activity can offer insight into internal confidence, valuation perceptions, and potential inflection points.
11,898 total articles
Emeritus director and 10% owner Jack W. Schuler purchased 82,465 shares of Biodesix on January 22, 2026, paying $903,560 in aggregate. The purchase raises the holdings of the Jack W. Schuler Living Trust to 1,463,210 shares. Separately, Biodesix disclosed preliminary fourth-quarter and full-year 2025 revenue that exceeded its guidance, while prior-…
Director Lawrence Cheng purchased 5,000 shares of GameStop Corp. on January 23, 2026, in a transaction valued at $114,368, according to a Form 4 filing with the Securities and Exchange Commission. The buy was executed at a weighted average price of $22.8737 per share. Separately, Chairman and CEO Ryan Cohen disclosed performance-based stock awards …
William M. Gottwald, a roughly 10% owner of Tredegar Corp (TG), sold 79,092 shares across January 22-23, 2026, realizing $683,494, according to a filed Form 4. The stock trades near $8.56 with a market capitalization of $292.23 million, carries a high P/E multiple, but also shows a free cash flow yield of 7%. Separately, Tredegar finalized a CEO su…
Stilwell Joseph, identified as a 10% owner of Peoples Financial Corp (NASDAQ: PFBX), acquired 1,840 shares of the company's common stock on January 23, 2026, at $20.50 per share, for a total cash outlay of $37,720. The filing details Stilwell's aggregate holdings through multiple Stilwell-managed investment vehicles and includes a disclaimer regard…
James T. Gottwald, identified as a ten percent owner of Tredegar Corporation (TG), disposed of 79,092 shares across two days in late January 2026 for roughly $683,494. The Form 4 filing details the tranches, weighted average prices and price ranges. Following the sales, Gottwald retains a mix of direct and indirect holdings across several trusts an…
John D. Gottwald, a roughly 10% owner of Tredegar Corporation, sold 79,092 shares of common stock on January 22 and 23, 2026, for a total of $683,494, according to a Form 4 filing. The transactions leave Gottwald with substantial direct and indirect holdings, while the company navigates a scheduled CEO transition and trades near InvestingPro's fair…
Abbott Laboratories Chairman and CEO Robert B. Ford reported a personal purchase of 18,800 shares on January 23, 2026, totaling $2,013,966. The transaction occurred in a price band of $106.735 to $107.485 and leaves Ford with 253,305 shares directly and 216,203 indirectly through the Ford Family Trust. The trade coincides with multiple analyst upda…
Abbott Laboratories Chairman and CEO Robert B. Ford acquired 18,800 common shares on January 23, 2026, for approximately $2.01 million. The move comes as the company reported weaker-than-expected fourth-quarter results and multiple analysts adjusted price targets and outlooks amid revenue and earnings shortfalls.
Trina M. Evans, a director at KeyCorp, sold 32,695 shares on January 22, 2026, generating roughly $710,789, and on the same day exercised options to acquire 8,695 shares at $18.96 each. The move came as KeyCorp reported fourth-quarter 2025 results that topped analyst forecasts on both earnings per share and revenue, yet the stock declined in premar…
Apellis Pharmaceuticals Chief Executive Cedric Francois sold 27,192 shares on January 22, 2026, for $21.7654 per share, raising $591,844 to cover tax withholding on restricted stock units released a day earlier. The company reported preliminary U.S. product revenue for fiscal 2025 of $689 million, with revenue split between Syfovre and Empaveli, a …
Brian M. Venturo, Chief Strategy Officer at CoreWeave, sold 283,100 shares of Class A common stock on January 21, 2026, under a pre-arranged 10b5-1 trading plan, generating $25.8 million in proceeds. On the same day he converted 281,250 Class B shares into Class A shares. Following these transactions, filings show his indirect and direct holdings s…
Bowman Consulting Group Ltd. CEO Gary Bowman sold 20,000 shares of common stock on January 21, 2026, at $35.37 per share under a Rule 10b5-1 plan, generating $707,400 in proceeds. The transactions were split between direct and indirect sales and fall within pre-authorized limits that permit additional sales through September 2026. Separately, the e…
Royalty Pharma plc Executive Vice President and Chief Financial Officer Terrance P. Coyne sold 69,582 Class A ordinary shares on January 20, 2026, generating roughly $2.7 million. The disposals were executed under a pre-arranged 10b5-1 trading plan adopted in August 2025. Royalty Pharma also reported a record $10 billion royalty funding market in 2…
American Eagle Outfitters director Noel Joseph Spiegel sold 1,896 shares on January 21, 2026, for $25.665 per share, realizing $48,660. The retailer has recently updated its fourth-quarter operating income guidance higher and signed a five-year global ambassador partnership. Analysts remain split on valuation and outlook.
Teresa A. Jones, an Executive Vice President at Costco Wholesale Corp, sold 850 shares on January 21, 2026, at a weighted-average price of $986.2567, for proceeds totaling $838,318. The transaction left Jones with 4,227.804 shares. The company also declared a quarterly cash dividend and reported healthy December sales growth, prompting varied analy…
Akamai Technologies Chief Technology Officer Robert Blumofe sold 3,500 shares on January 22, 2026, under a Rule 10b5-1 plan, generating $339,500. The company has recently received several analyst upgrades and has announced strategic partnerships and security certifications tied to its AI and cloud initiatives.
Bradley W. Hicks, President of DCS at J.B. Hunt Transport Services Inc., sold 3,919 shares on January 22, 2026, for roughly $823,512. The company reported fourth-quarter EPS of $1.90, beating consensus estimates, raised its quarterly dividend to $0.45, and announced a partnership with the Triumph Network to accelerate carrier payments.
Olivia Nottebohm, Chief Operating Officer of Box Inc., sold 4,612 Class A shares on January 21, 2026, under a Rule 10b5-1 plan for a weighted average price of $26.041, bringing proceeds of $120,101. Box reported Q3 2025 revenue of $301 million, beating consensus of $297.46 million, while EPS of $0.31 marginally missed the $0.32 estimate. Analyst ra…
A consortium including Nicholas S. Schorsch, Bellevue Capital Partners, LLC, and AR Global Investments, LLC bought a total of $57,725 of American Strategic Investment Co. Class A shares between January 20 and January 23, 2026. The transactions were executed at prices between $10.38 and $10.77 and were reported with transaction code "P." The purchas…
John Walter Hanna Jr., President and CEO of CareDx, Inc., sold 19,480 shares of company stock through pre-arranged trades in January 2026, totaling $412,222. The sales occurred across two days with prices ranging from $21.00 to $21.43 per share. Despite this decrease, Hanna maintains direct ownership of over 597,000 shares. CareDx reported strong f…
Axsome Therapeutics CFO Nick Pizzie sold 12,000 shares on January 22, 2026, for $2,255,040 and simultaneously exercised options to purchase 12,000 shares at $3.50 each. The stock has climbed near its 52-week high after an 80% gain over the past year; the company also announced preliminary unaudited Q4 2025 product revenue of about $196 million, up …
Jonathan S. Beatty, Managing Director and Head of Advisor Services at Charles Schwab, sold 2,000 shares of the firm's common stock on January 22, 2026, for $210,003 under a pre-arranged Rule 10b5-1 plan and on the same day exercised options to acquire 2,000 shares at $46.39. The move comes as Charles Schwab reported fourth-quarter results that met …
Joseph E. Gilliam, President and COO of Glaukos Corp, sold 4,502 shares of company stock totaling $561,174 on January 21, 2026. Concurrently, he exercised stock options to acquire an equal number of shares. These moves coincide with Glaukos reporting a significant 36% year-over-year increase in preliminary Q4 2025 revenue and positive analyst outlo…
Ari Maizel, Chief Commercial Officer of Axsome Therapeutics Inc, conducted a significant stock sale alongside exercising options, against a backdrop of notable revenue growth and positive analyst sentiment. The transactions occurred while Axsome's shares traded near yearly highs, underscoring investor interest amid the company's expanding commercia…
Kevin J. O’Connor, a director at Procore Technologies, has sold approximately $984,268 worth of company shares through a planned trading program, while Procore strengthens its market position through acquisitions and favorable analyst reviews. The company recently acquired Datagrid to enhance AI capabilities, saw positive analyst upgrades tied to a…
